Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T30085 | Target Info | |||
| Target Name | Sodium/glucose cotransporter 2 (SGLT2) | ||||
| Synonyms |
Solute carrier family 5 member 2; Na(+)/glucose cotransporter 2; Low affinity sodium-glucose cotransporter
Click to Show/Hide
|
||||
| Target Type | Successful Target | ||||
| Gene Name | SLC5A2 | ||||
| Biochemical Class | Solute:sodium symporter | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Sodium/glucose cotransporter 2 (SLC5A4) | Clinical trial Target | ||||
| UniProt ID | SC5A4_HUMAN | |||||
| Gene Name | SLC5A4 | |||||
| Synonyms |
Sodium/glucose cotransporter 4; SLC5A4
Click to Show/Hide
|
|||||
| Representative Drug(s) | PF-04971729 | Drug Info | IC50 = 0.877 nM | Click to Show More | [1] | |
| 2 | Dapagliflozin | Drug Info | IC50 = 1.35 nM | [2] | ||
| Co-Target Name | Sodium/glucose cotransporter 1 (SGLT1) | Clinical trial Target | ||||
| UniProt ID | SC5A1_HUMAN | |||||
| Gene Name | SLC5A1 | |||||
| Synonyms |
Solute carrier family 5 member 1; Na(+)/glucose cotransporter 1; NAGT; High affinity sodium-glucose cotransporter
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dapagliflozin | Drug Info | IC50 = 3.2 nM | Click to Show More | [3] | |
| 2 | Drug Info | IC50 = 34.6 nM | [4] | |||
| 3 | Canagliflozin | Drug Info | IC50 = 265 nM | [4] | ||
| 4 | PF-04971729 | Drug Info | IC50 = 392 nM | [4] | ||
| Co-Target Name | Sodium/myo-inositol cotransporter 2 (SLC5A11) | Co-Target | ||||
| UniProt ID | SC5AB_HUMAN | |||||
| Gene Name | SLC5A11 | |||||
| Synonyms |
Na(+)/myo-inositol cotransporter 2; Sodium-dependent glucose cotransporter; Sodium/glucose cotransporter KST1; Sodium/myo-inositol transporter 2; SMIT2; Solute carrier family 5 member 11
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dapagliflozin | Drug Info | IC50 = 380 nM | [5] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. | ||||
| REF 2 | Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3759-63. | ||||
| REF 3 | C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4465-70. | ||||
| REF 4 | Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. J Med Chem. 2017 May 25;60(10):4173-84. | ||||
| REF 5 | Discovery of non-glucoside SGLT2 inhibitors. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2472-5 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.